Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer

Expert Review of Anticancer Therapy

Volumn 6, Issue 9, 2006, Pages 1179-1193

  Astsaturov, Igor ^a   Cohen, Roger B ^a   Harari, Paul ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Cetuximab; Epidermal growth factor receptor; Head and neck cancer; Radiation; Tyrosine kinase inhibitor

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BEXAROTENE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EKB 659; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; HYDROXYUREA; ICR 62; IRINOTECAN; LAPATINIB; MATUZUMAB; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PLATINUM DERIVATIVE; PROTEIN P53; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ACNE; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CHILL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CARCINOMA; HEADACHE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LARYNGECTOMY; LARYNX CANCER; MUCOSA INFLAMMATION; NAUSEA; NONHUMAN; ODYNOPHAGIA; PARONYCHIA; PROTEIN EXPRESSION; RADIOSENSITIZATION; REVIEW; SIGNAL TRANSDUCTION; SKIN EXFOLIATION; SKIN MANIFESTATION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA;

DRUG DELIVERY SYSTEMS; HEAD AND NECK NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 33750071069     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.9.1179     Document Type: Review

References (137)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin. 56(2), 106-130 (2006).
2. Herrero R, Castellsague X, Pawlita M et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 95(23), 1772-1783 (2003).
3. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int. J. Cancer 114(5), 806-816 (2005).
4. Bentzen SM, Atasoy BM, Daley FM et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J. Clin. Oncol. 23(24), 5560-5567 (2005).
5. Bentzen SM. Repopulation in radiation oncology: perspectives of clinical research. Int. J. Radiat. Biol. 79(7), 581-585 (2003).
6. Elkind MM. The initial part of the survival curve: does it predict the outcome of fractionated radiotherapy? Radiat. Res. 114(3), 425-436 (1988).
7. Bourhis J, Amand C, Pignon J. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head and Neck Cancer) database focused on concomitant 14 chemoradiotherapy. J. Clin. Oncol. 22(14 Suppl.), 5505 (2004).
8. Kufe D. In: Cancer Medicine, 6th Edition. Decker BC (Ed.). Hamilton, ON, Canada 2v (2003).
9. Calais G, Alfonsi M, Bardet E et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 91(24), 2081-2086 (1999).
10. Brizel DM, Albers ME, Fisher SR et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 338(25), 1798-1804 (1998).
11. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355(9208). 949-955 (2000).
12. Adelstein DJ, Li Y, Adams GL et al. An intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. 21(1), 92-98 (2003).
13. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med. 349(22), 2091-2098 (2003).
14. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 350(19), 1945-1952 (2004).
15. Laramore GE, Scott CB, al-Sarraf M et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int. J. Radiat. Oncol. Biol. Phys. 23(4), 705-713 (1992).
16. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 23(11), 2445-2459 (2005).
17. Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transduction pathways in colorectal cancer - more than skin deep. J. Clin. Oncol. 23(23), 5374-5385 (2005).
18. Venook AP. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer 103(12), 2435-2446 (2005).
19. Johnson BE, Janne PA. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res. 65(17), 7525-7529 (2005).
20. Ramalingam S, Belani CP. Molecularly-targeted therapies for non-small cell lung cancer. Expert Opin. Pharmacother. 6(15), 2667-2679 (2005).
21. Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78(6), 1284-1292 (1996).
22. Rubin Grandis J, Melhem MF, Gooding WE et al. Levels of TCF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl Cancer Inst. 90(11), 824-832 (1998).
23. Cohen S. The stimulation of epidermal proliferation by a specific protein (EGF). Dev. Biol. 12(3), 394-407 (1965).
24. Cohen S, Carpenter G, King L Jr. Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J. Biol. Chem. 255(10), 4834-4842 (1980).
25. Ushiro H, Cohen S. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J. Biol. Chem. 255(18), 8363-8365 (1980).
26. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 44(3), 1002-1007 (1984).
27. Mendelsohn J. Growth factor receptors as targets for antitumor therapy with monoclonal antibodies. Prog. Allergy 45147-45160 (1988).
28. Downward J, Yarden Y, Mayes E et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307(5951), 521-527 (1984).
29. Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 53(18), 4322-4328 (1993).
30. Baselga J, Norton L, Masui H et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl Cancer Inst. 85(16), 1327-1333 (1993).
31. Balaban N, Moni J, Shannon M, Dang L, Murphy E, Goldkorn T. The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Biochim. Biophys. Acta 1314(1-2), 147-156 (1996).
32. Schmidt-Ullrich RK, Mikkelsen RB, Dent P et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15(10), 1191-1197 (1997).
33. Sheridan MT, O'Dwyer T, Seymour CB, Mothersill CE. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat. Oncol. Investig. 5(4), 180-186 (1997).
34. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin. Cancer Res. 5(10), 2884-2890 (1999).
35. Saleh MN, Raisch KP, Stackhouse MA et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFR antibody C225 and radiation. Cancer Biother. Radiopharm. 14(6), 451-463 (1999).
36. Milas L, Fan Z, Andratschke NH, Ang KK. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int. J. Radiat. Oncol. Biol. Phys. 58(3), 966-971 (2004).
37. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59(8), 1935-1940 (1999).
38. Milas L, Mason K, Hunter N et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. 6(2), 701-708 (2000).
39. Harari PM, Huang S. Radiation combined with EGFR signal inhibitors: head and neck cancer focus. Semin. Radiat. Oncol. 16(1), 38-44 (2006).
40. Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int. J. Radiat. Oncol. Biol. Phys. 58(2), 344-352 (2004).
41. Dassonville O, Formento JL, Francoual M et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J. Clin. Oncol. 11(10), 1873-1878 (1993).
42. Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 62(24), 7350-7356 (2002).
43. Vanhoefer U, Tewes M, Rojo F et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. 22(1), 175-184 (2004).
44. Crombet T, Osorio M, Cruz T et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J. Clin. Oncol. 22(9), 1646-1654 (2004).
45. Tyagi P. Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer. Clin. Colorectal Cancer 5(1), 21-23 (2005).
46. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99(3), 754-758 (2002).
47. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21(21), 3940-3947 (2003).
48. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7(4), 301-311 (2005).
49. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5(4), 317-328 (2004).
50. Sigismund S, Woelk T, Puri C et al. Clathrin-independent endocytosis of ubiquitinated cargos. Proc. Natl Acad. Sci. USA 102(8), 2760-2765 (2005).
51. Puri C, Tosoni D, Comai R et al. Relationships between EGFR signaling-competent and endocytosis-competent membrane microdomains. Mol. Biol. Cell 16(6), 2704-2718 (2005).
52. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354(6), 567-578 (2006).
53. Robert F, Ezekiel MP, Spencer SA et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 19(13), 3234-3243 (2001).
54. Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18(4), 904-914 (2000).
55. Shin DM, Donato NJ, Perez-Soler R et al Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 7(5), 1204-1213 (2001).
56. Bonner JA, Raisch KP, Trummell HQ et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J. Clin. Oncol. 18(Suppl. 1), S47-S53 (2000).
57. Bonner JA, Harari PM, Giralt J et al. Cetuximab improves locoregional control and survival of locoregionally advanced head and neck cancer: independent review of mature data with a median followup of 45 months. AACR-NCI-EORTC International Conference. Mol. Targets Cancer Ther. Clin. Cancer Res. 11(24 Pt 2), S9058 (2005).
58. Geisler SA, Olshan AF, Weissler MC et al. p16 and p53 protein expression as prognostic indicators or survival and disease recurrence from head and neck cancer. Clin. Cancer Res. 8(11), 3445-3453 (2002).
59. Pfister DG, Su YB, Kraus DH et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot Phase II study of a new combined-modality paradigm. J. Clin. Oncol. 24(7), 1072-1078 (2006).
60. Diaz E, Sturgis E, Laramore G, Sabichi A, Lippman S, Clayman G. Neoplasms of the head and neck. In: Cancer Medicine, 6th Edition. Kufe D, Bast R Jr, Hait W (Eds). 21325-21371 (2003).
61. Benchalal M, Bachaud JM, Francois P et al. Hyperfractionation in the reirradiation of head and neck cancers. Result of a pilot study. Radiother. Oncol 36(3), 203-210 (1995).
62. Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 24(17), 2659-2665 (2006).
63. Trigo R, Hitt P, Koralewski E et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a Phase II study. ASCO Annual Meeting (2004).
64. Saltz LB, Lenz H, Hochster H et al. Randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. ASCO Annual Meeting (2005).
65. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004).
66. Baselga J, Trigo JM, Bourhis J et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23(24), 5568-5577 (2005).
67. Herbst RS, Arquette M, Shin DM et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23(24), 5578-5587 (2005).
68. Vermorken J. Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies. J. Clin. Oncol. 23(16 Suppl.), 5505 (2005).
69. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 23(34), 8646-8654 (2005).
70. Vermorken JB, Mesia R, Vega-Villegas ME, Remenar E, Hitt R, Kawecki A. Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 24(18 Suppl.), 5537 (2006).
71. Bier H, Hoffmann T, Haas I, van Lierop A. And-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol. Immunother. 46(3), 167-173 (1998).
72. Trarbach T, Schleucher N, Weber D et al. Phase I study of the humanized anti-epidermal growth factor receptor (EGFR) antibody FMD 72000 (matuzumab) in combination with cisplatin, 5-fluorouracil and leucovorin (PFL) in patients (pts) with advanced esophago-gastric (EG) adenocarcinoma. J. Clin. Oncol. 23(16 Suppl.), 3156 (2005).
73. Panousis C, Rayzman VM, Johns TG et al. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. Br. J. Cancer 92(6), 1069-1077 (2005).
74. Jungbluth AA, Stockert E, Huang HJ et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc. Natl Acad. Sci. USA 100(2), 639-644 (2003).
75. Erlichman C, Hidalgo M, Boni JP et al. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. 24(15), 2252-2260 (2006).
76. Cohen EE, Rosen F, Stadler WM et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 21(10), 1980-1987 (2003).
77. Kirby AM, A'Hern RP, D'Ambrosio C et al. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br. J. Cancer 94(5), 631-636 (2006).
78. Cohen EE, Kane MA, List MA et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin. Cancer Res. 11(23), 8418-8424 (2005).
79. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 22(1), 77-85 (2004).
80. Belon J, Irigoyen A, Rodriguez I et al. Preliminary results of a Phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck. J. Clin. Oncol. 23(16 Suppl.), 5563 (2005).
81. Kim ES, Kies M, Sabichi A et al. Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). J. Clin. Oncol. 23(16 Suppl.), 5546 (2005).
82. Wirth LJ, Haddad RI, Lindeman NI et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23(28), 6976-6981 (2005).
83. Dragnev KH, Petty WJ, Shah S et al. Bexarotene and erlotinib for aerodigestive tract cancer. J. Clin. Oncol. 23(34), 8757-8764 (2005).
84. Callender T, el-Naggar AK, Lee MS, Frankenthaler R, Luna MA, Batsakis JG. PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer 74(1), 152-158 (1994).
85. Rhys-Evans P, Modjtahedi H, Eccles SA, O'Charoenrat P. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin. Exp. Metastasis 18(2), 155-161 (2000).
86. Vokes EE, Cohen EEW, Mauer AM et al. A Phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J. Clin. Oncol. 23(16 Suppl.), 5504 (2005).
87. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 64(15), 5355-5362 (2004).
88. Matar P, Rojo F, Cassia R et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin. Cancer Res. 10(19), 6487-6501 (2004).
89. Cohen EE, Haraf DJ, Stenson KM et al. Integration of gefitinib (G), into a concurrent chemoradiation (CRT) regimen followed by G adjuvant therapy in patients with locally advanced head and neck cancer (HNC) - a Phase II Trial. ASCO Annual Meeting Proceedings (2005).
90. Herchenhorn D, Dias FL, Araujo CM et al. Phase I/II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol. 23(16 Suppl.), 5596 (2005).
91. Doss H, Greco F, Meluch A et al. Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: a Phase I/II trial of the Minnie Pearl Cancer Research Network. ASCO Annual Meeting Proceedings 24(18S), S290 (2006).
92. Savvides P, Agarwala S, Greskovich J et al. Phase I study of the EGFR tyrosine kinase inhibitor erlobtinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). ASCO Annual Meeting Proceedings 24(18S), S291 (2006).
93. Burris HA III, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 23(23), 5305-5313 (2005).
94. Spector NL, Xia W, Burris H III et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol. 23(11), 2502-2512 (2005).
95. Cohen EE, Lingen MW, Martin LE et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin. Cancer Res. 11(22), 8105-8108 (2005).
96. Herrington KJ, Bourhis J, Nutting CM, Rosine D, Theodosiou AM, Gardiner S. A Phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol. 24(18 Suppl.), 5553 (2006).
97. Abidoye OO, Cohen EE, Wong SJ et al. A Phase II study of lapatinb in recurrent/metastatic squamous carcinoma of the head and neck. J. Clin. Oncol. 24(18 Suppl.), 5568 (2006).
98. Ryan AJ, Wedge SR. ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br. J. Cancer 92(Suppl. 1), S6-S13 (2005).
99. Traxler P, Allegrini PR, Brandt R et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 64(14), 4931-4941 (2004).
100. Fujii M, Yamashita T, Ishiguro R, Tashiro M, Kameyama K. Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. Auris Nasus Larynx 29(2), 175-181 (2002).
101. Chua DT, Nicholls JM, Sham JS, Au GK. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 59(1), 11-20 (2004).
102. Tao Y, Song X, Deng X et al. Nuclear accumulation of epidermal growth factor receptor and acceleration of G1/S stage by Epstein-Barr-encoded oncoprotein latent membrane protein 1. Exp. Cell Res. 303(2), 240-251 (2005).
103. Stevenson D, Charalambous C, Wilson JB. Epstein-Barr virus latent membrane protein 1 (CAO) up-regulates VEGF and TGF α concomitant with hyperlasia, with subsequent up-regulation of p16 and MMP9. Cancer Res. 65(19), 8826-8835 (2005).
104. Hsu CH, Gao M, Chen CL, Yeh PY, Cheng AL. Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro. Oncology 68(4-6), 538-547 (2005).
105. Tao YG, Tan YN, Liu YP et al. Epstein-Barr virus latent membrane protein 1 modulates epidermal growth factor receptor promoter activity in a nuclear factor κB-dependent manner. Cell Signal. 16(7), 781-790 (2004).
106. Chan AT, Hsu MM, Goh BC et al. Multicenter, Phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J. Clin. Oncol. 23(15), 3568-3576 (2005).
107. Lee SC, Lim SG, Soo R et al. Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. Pharmacogenet. Genomic 16(1), 73-74 (2006).
108. Vered M, Braunstein E, Buchner A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 24(7), 632-636 (2002).
109. Glisson BS, Blumenschein G, Francisco M, Erasmus J, Zinner R, Kies M. Phase II trial of gefitinib in patients with incurable salivary gland cancer. ASCO Annual Meeting (2005).
110. Agulnik M, Cohen EE, Cohen RB et al. A Phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) or non-ACC malignant tumors of the salivary gland. J. Clin. Oncol. 24(18 Suppl.), 5566 (2006).
111. Licitra L, Locati L, Potepan P et al. Cetuximab (C225) in recurrent and/ or metastatic salivary gland carcinomas (RMSGCs): a monoinstitutional Phase II study. ASCO Annual Meeting Proceedings 24(18 Suppl.), S291 (2006).
112. Ensinger C, Spizzo G, Moser P et al. Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann. NY Acad. Sci. 103069-103077 (2004).
113. Schiff BA, McMurphy AB, Jasser SA et al. Epidermal growth factor receptor (ECFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin. Cancer Res. 10(24), 8594-8602 (2004).
114. Nobuhara Y, Onoda N, Yamashita Y et al. Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br. J. Cancer 92(6), 1110-1116 (2005).
115. Kim S, Prichard CN, Younes MN et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin. Cancer Res. 12(2), 600-607 (2006).
116. Holting T, Siperstein AE, Clark OH, Duh QY. Epidermal growth factor (EGF)- and transforming growth factor - stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur. J. Endocrinol. 132(2), 229-235 (1995).
117. Gabler B, Aicher T, Heiss P, Senekowitsch-Schmidtke R. Growth inhibition of human papillary thyroid carcinoma cells and multicellular spheroids by anti-EGF-receptor antibody. Anticancer Res. 17(4B), 3157-3159 (1997).
118. Wells S, You Y, Lakhani V et al. A Phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. ASCO Annual Meeting Proceedings 24(18S), S288 (2006).
119. Milas L, Mason KA, Ang KK. Epidermal growth factor receptor and its inhibition in radiotherapy: in vivo findings. Int. J. Radiat. Biol. 79(7), 539-545 (2003).
120. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J. Histochem. Cytochem. 52(7), 893-901 (2004).
121. Johnson GA, Mannel R, Khalifa M et al. Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. Gynecol. Oncol. 65(3), 425-429 (1997).
122. Haber DA, Bell D, Sordella R, Lynch T, Settleman J. Activating mutations in the epidermal growth factor receptor underlie responsiveness of non-small cell lung cancer to the tyrosine kinase inhibitor Gefitinib. Presented at: Am. Assoc. Cancer Res. 96th Annual Meeting, April 17 (2005).
123. Price DK, Figg WD. Mutations in the EGFR: the importance of genotyping. Cancer Biol. Ther. 3(5), 434-435 (2004).
124. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
125. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 23(11), 2556-2568 (2005).
126. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101(36), 13306-13311 (2004).
127. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur. J. Cancer 42(1), 109-111 (2006).
128. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 23(11), 2556-2568 (2005).
129. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500 (2004).
130. Willmore-Payne C, Holden JA, Layfield LJ. Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod. Pathol. 19(5), 634-640 (2006).
131. Lee JW, Soung YH, Kim SY et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 11(8), 2879-2882 (2005).
132. Amador ML, Oppenheimer D, Perea S et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 64(24), 9139-9143 (2004).
133. Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6(5), 279-286 (2005)
134. Hirsch FR, Varella-Garcia M, McCoy J et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J. Clin. Oncol. 23(28), 6838-6845 (2005).
135. Gordon AN, Finkler N, Edwards RP et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a Phase II multicenter study. Int. J. Gynecol. Cancer 15(5), 785-792 (2005).
136. Tang PA, Tsao MS, Moore MJ. A review of erlotinib and its clinical use. Expert Opin. Pharmacother. 7(2), 177-193 (2006).
137. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/ EGFR-targeted agents: is there a silver lining? J. Clin. Oncol. 23(22), 5235-5246 (2005).